FIA
ACRS icon

FNY Investment Advisers’s Aclaris Therapeutics ACRS Stock Holding History

FNY Investment Advisers’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$12 – 437
2024
Q1 		$12 Buy
+10,000
New +$11.9K 0.01% 431

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

FNY Investment Advisers's ACRS Position: Q2 2024 in Review

FNY Investment Advisers sold out of Aclaris Therapeutics (ACRS) in Q2 2024, closing a stake of 10,000 shares — an estimated $12 sold.

FNY Investment Advisers first reported a position in ACRS in Q1 2024 and held it in 1 quarter. The position peaked at $12 in Q1 2024. 98 funds tracked by Wall St. Rank hold ACRS as of Q2 2024.

  • FNY Investment Advisers reported no remaining Aclaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 10,000 Aclaris Therapeutics shares in Q2 2024, an estimated $12.
  • FNY Investment Advisers first reported a position in Aclaris Therapeutics in Q1 2024 and held it in 1 quarter.
  • FNY Investment Advisers's Aclaris Therapeutics position peaked at $12 in Q1 2024.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2024.

Based on FNY Investment Advisers's 13F filing for Q2 2024, filed 5 Aug 2024.